A TOTAL SYNTHESIS OF OXETANOCIN, A NOVEL NUCLEOSIDE WITH AN OXETANE RING

Shigeru Nishiyama, Shosuke Yamamura,\* Kuniki Kato,<sup>†</sup> and Tomohisa Takita<sup>†</sup> Department of Chemistry, Faculty of Science and Technology, Keio University Hiyoshi, Yokohama, Japan

+ Research Laboratories, Pharmaceutical Groups, Nippon Kayaku Co. Ltd., 3-31-12 Shimo, Kita-ku, Tokyo 115, Japan

Summary: Oxetanocin has been synthesized starting from cis-2-buten-1,4-diol through  $\angle$ - or  $\beta$ -D-oxetanosyl acetate as an important intermediate which has an  $\angle$ -(methyl oxalyloxy)methyl group at  $C_2$ -position.

As described in the preceding paper,  $^1$  oxetanocin with antiviral, antitumor and antibacterial activities is regarded as the first oxetanosyl-N-glycoside,  $^2$  and its synthesis has been accomplished by Niitsuma et al.  $^3$  However, their synthetic method is only limited to oxetanocin (1). We describe herein a general method to synthesize oxetanocin and related nucleosides. In the light of our important results,  $^4$  retrosynthesis of oxetanocin (1) is shown in Scheme 1, wherein an  $\mathcal{L}$ -(methyl oxalyloxy)methyl group at  $^2$ -position operates to yield a favorable intermediate with a seven-membered ring on treatment of  $^2$  with Lewis acid.

R : Me, Et, Bu $^{\mathsf{t}}$  and phenyl groups

Scheme 1. Retrosynthesis of oxetanocin.

The known diol (3),  $^5$  derived from cis-2-buten-1,4-diol, was readily converted into two monohydroxy compounds (4 and  $5)^6$  in 2 steps [1) p-MeOC<sub>6</sub>H<sub>4</sub>CHO - TsOH, benzene (refluxing temp., 3 h); 2) DIBAL-H, toluene (room temp., 3 h) (85% overall yield (4/5 = 2))]. The latter was reconverted into the original diol (3) using DDQ, whereas 4 was further treated with  $(Bu^t)Me_2SiCl$  - imidazole in DMF (room temp., 1.5 h) to afford a silyl ether, in 91% yield, which was directly converted into two epimers  $(6 \text{ and } 7)^6$  in 2 steps [1)  $0sO_4$  (cat) - NMMO, acetone -  $H_2O$  -  $Bu^tOH$  (room temp., 2 days); 2)  $CH_2$ =CHCH<sub>2</sub>Br - NaH, THF (room temp., 15 h) (58% overall yield (6/7 = 1/3))]. On Mitsunobu reaction followed by hydrolysis [1) PhCOOH - Ph<sub>3</sub>P - DEAD, THF (room temp., 20 h); 2)  $K_2CO_3$ , MeOH (room temp., 15 h)], the latter was converted

into 6 in 47% yield. Therefore, the total yield of 6 from 4 was 32%. The compound (6) so far obtained was treated with MsCl - Et<sub>3</sub>N in  $CH_2Cl_2$  (room temp., 3 h) and then deprotected with DDQ in  $CH_2Cl_2$  -  $H_2O$  (room temp., 3 h) to afford the corresponding mesylate (8), 6 in 65% overall yield, from which an oxetane (9) was produced in 3 steps [1) 60% NaH (1.6 equiv), THF (room temp., overnight) (84%); 2) RhCl(Ph<sub>3</sub>P)<sub>3</sub> - DABCO (refluxing temp., 6 h); 3) HgO - HgCl<sub>2</sub>, acetone (room temp., 2 h) (65% in 2 steps)].

As described in the preceding paper,  $^1$  in the next step, the oxetane (9) was readily converted into a methyl ketone ( $^{10}$ ) in 3 steps [1) ( $^{10}$ ) colling - DMSO - Et<sub>3</sub>N,  $^{10}$ CH<sub>2</sub>Cl<sub>2</sub> (-45 °C, 30 min); 2) MeMgI, Et<sub>2</sub>O (0 °C, 2 h) (87% in 2 steps); 3) DCC - DMSO - pyridine -TFA, benzene (room temp., overnight) (51%)]. This ketone was further converted into an oxetane ( $^{11}$ ) with the desired two different functional groups, in 4 steps [1) (Bu<sup>n</sup>)<sub>4</sub>NF, THF (0 °C, 1 h) (69%); 2) MeOOCCOCl - pyridine, CH<sub>2</sub>Cl<sub>2</sub> (-23 - 10 °C, 2.5 h) (95%); 3) H<sub>2</sub>/Pd-black, THF (room temp., 20 min); 4) C<sub>2</sub>H<sub>5</sub>COCl - pyridine, CH<sub>2</sub>Cl<sub>2</sub> (0 °C, 1 h) (66% in 2 steps)]. Baeyer-Villiger oxidation of 11 was carried out using mCPBA in CH<sub>2</sub>Cl<sub>2</sub> (4 °C, overnight) to afford the corresponding  $\beta$ -D-oxetanosyl acetate (12) in quantitative yield.

Finally, the acetate  $(12)^7$  so far obtained was subjected to condensation reaction with


N-benzoyl-disilyladenine in 1,2-dichloroethane (room temp., 30 min) using  $SnCl_4$  as Lewis acid, followed by hydrolysis [0.15N NaOMe, MeOH (room temp., 4.5 h)]<sup>8</sup> and then benzoylation [BzCl -pyridine,  $CH_2Cl_2$  (room temp., overnight)] to afford three condensation products (13, 14 and 15) in 16, 10 and 6.3% overall yields, respectively. The first one was completely identical with the dibenzoate (13)<sup>6</sup> derived from natural oxetanocin (1) in all respects of spectral data, whereas the second one was N,N-dibenzoylepioxetanocin dibenzoate (14).<sup>6</sup> The stereostructure (15) of the remaining product is based on its spectral data.<sup>9</sup> Clearly, the four-membered ring of the oxetanose is cleaved and then recyclized to afford the corresponding furanoside (15).

According to essentially the same synthetic procedure as described above, we also synthesized an  $\mathcal{L}$ -D-oxetanosyl acetate (16)<sup>6</sup> from 7. This acetate (16) was also treated successively with N-benzoyl-disilyladenine -  $SnCl_4$ , 0.15N NaOMe and then benzoyl chloride - pyridine to give both 13 and 14 in 26 and 8.7% overall yields, respectively. On hydrolysis with 0.1N NaOMe in MeOH (room temp., overnight), these two dibenzoates (13 and 14) were readily converted into oxetanocin (1) and epioxetanocin (17)<sup>10</sup> in 81 and 77% yields, respectively.

Further synthetic studies on other nucleosides related to exetanocin are in progress.

## References

- 1. Submitted to Tetrahedron Letters.
- N. Shimada, S. Hasegawa, T. Harada, T. Tomisawa, A. Fujii, and T. Takita, J. Antibiot., 39, 1623 (1986);
   H. Nakamura, S. Hasegawa, N. Shimada, A. Fujii, T. Takita, and Y. Iitaka, ibid., 39, 1629 (1986).
- 3. S. Niitsuma, Y. Ichikawa, K. Kato, and T. Takita, Tetrahedron Lett., 28, 1967, 4713 (1987).
- 4. In the case of the dibenzoate [A],  $^1$  only  $\mathcal{L}$ -N-glycoside (14) has been produced through a favorable intermediate [B] with a seven-membered ring, as shown below.



- 5. M. A. Tius and H. Fauq, J. Org. Chem., 48, 4132 (1983).
- 6. The spectral data for the new compounds are in accord with the structures assigned, and only selected data are cited: 4: C21H26O4 [m/z 342.1817(M+)]; IR (film) 3400 and 1610 cm-1; \$ (CDCl3) 2.51(1H, m), 3.53(1H, dd, J= 5, 10 Hz), 3.63(3H, complex), 3.79(3H, s), 4.50(1H, d, J= 11 Hz), 4.52(2H, s), 4.66(1H, d, J= 11 Hz), 5.15(2H, complex), 5.81(1H, m), 6.86(2H, d, J= 8.8 Hz), 7.25(2H, d, J= 8.8 Hz) and 7.33(5H, complex). 5: C21H26O4 [m/z 342.1833(M+)]; \$ (CDCl3) 2.50(1H, m), 3.4 3.5(2H, complex), 3.53(1H, dd, J= 5, 9 Hz), 3.61(1H, dd, J= 6.3, 9 Hz), 3.79(3H, s), 4.05(1H, m), 4.43(2H, s), 4.50(1H, d, J= 12 Hz), 4.53(1H, d, J= 12 Hz), 5.15(2H, complex), 5.88(1H, m), 6.86(2H, d, J= 8 Hz), 7.22(2H, d, J= 8 Hz) and 7.32(5H, complex). 6: C30H46O6Si [m/z 530.3046(M+)]; IR (film) 3520 cm-1; \$ (CDCl3) 0.87(9H, s), 2.00(1H, m), 3.77(3H, s), 3.4 3.85(6H, complex), 3.97(3H, complex), 4.10(1H, m), 4.47(1H, d, J= 9 Hz), 4.52(2H, s), 4.67(1H, d, J= 9 Hz), 5.0 5.3(2H, complex), 5.76(1H, m), 6.82(2H, d, J= 9 Hz), 7.23(2H, d, J= 9 Hz) and 7.30(5H, s). 7: C30H46O6Si [m/z 530.3056(M+)]; IR (film) 3500 cm-1; \$ (CDCl3) 0.80(9H, s), 1.98(1H, m), 3.4 3.7(6H, complex), 3.83(3H, s), 3.93(4H, complex), 4.42(1H, d, J= 12 Hz), 4.47(2H, s), 4.62(1H, d, J= 12 Hz), 5.0 5.3(2H, complex), 5.80(1H, m), 6.78(2H, d, J= 9 Hz), 7.22(2H, d, J= 9 Hz) and 7.27(5H, s). 8: C23H40O7SSi [m/z 488.2254(M+)]; IR (film) 3550 and 1645

- cm<sup>-1</sup>; \$(CDCl<sub>3</sub>) 0.83(9H, s), 2.03(1H, m), 3.03(3H, s), 3.4 4.0(9H, complex), 4.50(2H, s), 5.1 5.3(3H, complex), 5.3(1H, m) and 7.28(5H, br.s). 9: C<sub>1</sub>9H<sub>3</sub>30<sub>4</sub>Si [m/z 353.2140 (M<sup>+</sup> + 1)]; IR (film) 3450 cm<sup>-1</sup>; \$(CDCl<sub>3</sub>) 0.04(6H, s), 0.88(9H, s), 3.27(1H, m, overlapped with 1H signal), 3.53(1H, dd, J= 3.4, 11.2 Hz), 3.5 3.6(1H, m), 3.70(1H, dd, J= 2.9, 11.2 Hz), 3.73(2H, d, J= 5.9 Hz), 3.82(1H, m), 4.58(1H, d, J= 12 Hz), 4.65(1H, d, J= 12 Hz), 4.65(1H, d, J= 12 Hz), aces [m/z 364.2064(M<sup>+</sup>)]; IR (film) 1715 cm<sup>-1</sup>; \$(CDCl<sub>3</sub>) 2.24(3H, s) and 4.76(1H, d, J= 6.8 Hz). 11: C<sub>11</sub>H<sub>15</sub>O<sub>7</sub> [m/z 259.0798(M<sup>+</sup> CH<sub>3</sub>CO)]; IR (film) 1770 and 1750 cm<sup>-1</sup>; \$(CDCl<sub>3</sub>) 1.12 (3H, t, J= 7.5 Hz), 2.25(3H, s), 2.35(2H, q, J= 7.5 Hz), 3.20(1H, m), 3.88(3H, s), 4.18 (2H, complex), 4.50(2H, d, J= 6 Hz) and 4.70(1H, d, J= 6 Hz), overlapped with 1H signal). 12: C<sub>11</sub>H<sub>15</sub>O<sub>7</sub> [m/z 259.0799(M<sup>+</sup> CH<sub>3</sub>COO)]; IR (film) 1775 and 1750 cm<sup>-1</sup>; \$(CDCl<sub>3</sub>) 1.15 (3H, t, J= 7.5 Hz), 2.08(3H, s), 2.38(2H, q, J= 7.5 Hz), 3.12(1H, m), 3.90(3H, s), 4.27 (2H, complex), 4.50(2H, d, J= 6 Hz, overlapped with 1H signal) and 6.22(1H, d, J= 3 Hz). 13: C<sub>31</sub>H<sub>2</sub>A<sub>2</sub>N<sub>5</sub>O<sub>6</sub> [m/z 562.1707(M<sup>+</sup> Bz)]; [A<sub>1</sub>O<sub>6</sub> 35.8° (c 0.63, CHCl<sub>3</sub>); IR (film) 1710, 1595, 1570 and 1490 cm<sup>-1</sup>; \$(CDCl<sub>3</sub>) 4.36(1H, m), 4.64(1H, dd, J= 4.9, 12.2 Hz), 4.70 (1H, dd, J= 5.4, 12.2 Hz), 4.84(1H, dd, J= 3.9, 12.7 Hz), 4.92(1H, dd, J= 5.4, 12.7 Hz), 5.07(1H, m), 6.61(1H, d, J= 5.9 Hz), 7.35(4H, complex), 7.45(6H, complex), 7.58(2H, complex), 7.85(4H, complex), 8.03(4H, complex), 8.03(4H, complex), 7.45(6H, complex), 7.58(2H, d, J= 5.5, 11.7 Hz), 4.56(1H, dd, J= 3, 11 Hz), 4.68(1H, dd, J= 3, 11 Hz), 4.80(1H, dd, J= 5.5, 11.7 Hz), 5.56(1H, dd, J= 5, 11.7 Hz), 4.56(1H, dd, J= 3, 11 Hz), 4.80(1H, dd, J= 5.5, 11.7 Hz), 5.56(1H, m), 6.45(1H, dd, J= 3, 11 Hz), 4.80(1H, dd, J= 5.5, 11.7 Hz), 5.56(1H, m), 6.45(1H, dd, J= 7.5 Hz), 2.12(3H, s), 2.38(2H, q, J= 7.5 Hz), 3.43(1H, m), 3.88(3H, s), 4.26(2H, complex), 7.85(6H, complex), 7.45(6H, dd, J= 7.5 Hz), 2.12(3H, s), 2.38(
- 7. The 

  √-(methyl oxalyoxy)methyl group at C2-position is not always better than other functional groups. For example, there remains a possibility that an eight-membered ring intermediate is more favorable than the seven-membered ring intermediate shown in Scheme 1. Further study on this point is in progress. In addition, pivaloyloxymethyl group was used instead of propionyloxymethyl group at C3-position. However, any good result has not yet been obtained. Other acyloxymethyl groups at C3-position are also examined in due course.
- 8. Both oxetanocin and epioxetanocin were detected on analytical TLC (Kieselgel  $PF_{254}$ ). At this stage, however, these two epimers were not obtained in a pure state.
- 9. The molecular ion peak of 15 was not observed in its mass spectrym, but its stereostructure was unambiguously confirmed by the spectral data:  $[\mathcal{A}]_0^{26}$  -55.7° (c 0.24, CHCl 3), IR (film) 1720 cm<sup>-1</sup>;  $\mathcal{E}$  (CDCl 3) 4.07(1H, m), 4.33(1H, br.d, J= 10.7 Hz), 4.71(1H, dd, J= 7.8, 11 Hz), 4.77(1H, dd, J= 6.4, 11 Hz), 4.85(1H, dd, J= 3.4, 10.7 Hz), 6.05(1H, m), 6.41(1H, d, J= 7.3 Hz), 7.37(6H, complex), 7.49(5H, complex), 7.63(1H, m), 7.68(2H, complex), 7.86(4H, complex), 8.07(2H, complex), 8.20(1H, s) and 8.62(1H, s).
- 10. The molecular ion peak of 17 has not been observed in its mass spectrum, but its structure is supported by the spectral data: IR (film) 3340, 1630br. and 1575 cm<sup>-1</sup>;  $\boldsymbol{\mathcal{S}}$  (DMSO-d<sub>6</sub>) 2.72(1H, m), 3.55(2H, complex), 3.92(1H, dd, J= 3, 9 Hz), 4.00(1H, dd, J= 5, 9 Hz), 4.23 (1H, m), 6.05(1H, d, J= 3.9 Hz), 8.15(1H, s) and 8.36(1H, s).

(Received in Japan 21 April 1988; accepted 27 June 1988)